^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | VIO-01 (PARP1 inhibitor, KU70/KU80 inhibitor, MRN complex inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1114 Immunotherapeutic activity of OX425 against PD-1 resistant HR+HER2- breast cancer
Published date:
11/08/2022
Excerpt:
OX425 was well tolerated, effective at controlling tumor growth and extending overall survival in mice….OX425 at doses < 500 µg/mice 2X per week is well tolerated in mice and mediates single-agent immunotherapeutic activity in models of PD-1-resistant HR+HER2- breast cancer...
DOI:
http://dx.doi.org/10.1136/jitc-2022-SITC2022.1114
